Carcinoid Tumors (DBCOND0030495)

Identifiers

Synonyms
Carcinoid tumour / Carcinoid tumours / Carcinoid Tumor / Benign carcinoid tumor of unspecified site / Carcinoid tumour NOS / Carcinoid tumor - morphology (morphologic abnormality) / Carcinoid tumor (disorder)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Pentetreotide
A somatostatin receptor inhibitor, available in a kit with Indium-111, used as a contrast agent in the visualization of somatostatin receptor-positive neuroendocrine tumours.
No drug targets
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT04907643
Virtual Reality for GI Cancer Pain to Improve Patient Reported OutcomesNo drug interventionssupportive_careNot Availablerecruiting
NCT01782443
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumorstreatment2completed
NCT02754297
Personalized PRRT of Neuroendocrine Tumorstreatment2active_not_recruiting
NCT00328497
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumorstreatment2completed
NCT00412061
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumortreatment3completed
NCT04993261
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid TumorsNo drug interventionsdiagnostic0active_not_recruiting
NCT02399215
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumorstreatment2completed
NCT01466036
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumorstreatment2completed
NCT04039516
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapytreatment2not_yet_recruiting
NCT01175096
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumortreatment1 / 2unknown_status
NCT02628067
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)treatment2recruiting
NCT05361668
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrometreatment2active_not_recruiting
NCT04197310
Cabozantinib and Nivolumab for Carcinoid Tumorstreatment2completed
NCT02038738
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumorsdiagnostic1 / 2unknown_status
NCT03420521
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumorstreatment2terminated
NCT04028479
The Registry of Oncology Outcomes Associated With Testing and TreatmentNo drug interventionsNot AvailableNot Availablerecruiting
NCT01024387
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumorstreatment2completed
NCT02431715
18F-FDOPA PET in Neuroendocrine TumoursNo drug interventionsNot AvailableNot Availableno_longer_available
NCT00657332
Clinical and Pathologic Studies in Neuroendocrine TumorsNo drug interventionsNot AvailableNot Availablewithdrawn
NCT03723499
Endoscopic Treatment of Bronchial Carcinoid TumorsNo drug interventionsNot AvailableNot Availablecompleted
NCT01398306
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.No drug interventionsNot AvailableNot Availablecompleted
NCT00804336
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumorstreatment1completed
NCT05636618
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine TumorsNo drug interventionstreatment1 / 2recruiting
NCT00780663
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinomatreatment2completed
NCT01435122
A Study of Axitinib in Advanced Carcinoid Tumorstreatment2completed
NCT01039922
SwissNET - a Registry for Neuroendocrine Tumours in SwitzerlandNo drug interventionsNot AvailableNot Availablerecruiting
NCT03375320
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumorstreatment3active_not_recruiting
NCT00446082
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Diseasetreatment1completed
NCT00942682
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumorstreatment1completed
NCT05477576
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapytreatment3recruiting
NCT04915144
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETstreatment2withdrawn
NCT04017104
Dynamic Whole Body Positron Emission Tomography/Computed Tomography ImagingNo drug interventionsNot AvailableNot Availableunknown_status
NCT02859064
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspherestreatment2terminated
NCT01253161
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)treatment2completed
NCT01373736
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine TumorsNo drug interventionsdiagnostic3unknown_status
NCT01619865
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumorsdiagnostic1 / 2completed
NCT00580320
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcomatreatment1completed
NCT02441062
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumorsdiagnostic2completed
NCT00947167
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumorstreatment2terminated
NCT00088595
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumorstreatment2completed
NCT01980732
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive TumorsNo drug interventionsNot AvailableNot Availableno_longer_available
NCT02359500
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)diagnostic1terminated
NCT02575300
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumorstreatment2completed
NCT00227136
Effect of Oral 5-HTP Intake on Urinary 5-HIAA ExcretionNo drug interventionsdiagnostic3terminated
NCT02795858
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumorstreatment2active_not_recruiting
NCT01731925
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumorstreatment2unknown_status
NCT02177773
GA-68 DOTA-TOC of Somatostatin Positive Malignanciesdiagnostic1 / 2terminated
NCT02441088
Theranostics: 68GaDOTATOC and 90YDOTATOCtreatment2active_not_recruiting